Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
41.42
+0.44 (1.07%)
At close: Aug 1, 2025, 4:00 PM
41.16
-0.26 (-0.63%)
After-hours: Aug 1, 2025, 5:06 PM EDT
Guardant Health Stock Forecast
Stock Price Forecast
The 18 analysts that cover Guardant Health stock have a consensus rating of "Strong Buy" and an average price target of $55.67, which forecasts a 34.40% increase in the stock price over the next year. The lowest target is $35 and the highest is $70.
Price Target: $55.67 (+34.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 10 | 8 |
Buy | 8 | 9 | 10 | 10 | 10 | 10 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 19 | 20 | 21 | 21 | 20 | 18 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Scotiabank | Scotiabank | Buy Maintains $57 → $60 | Buy | Maintains | $57 → $60 | +44.86% | Jul 31, 2025 |
Raymond James | Raymond James | Buy Maintains $59 → $61 | Buy | Maintains | $59 → $61 | +47.27% | Jul 31, 2025 |
Mizuho | Mizuho | Buy Maintains $60 → $65 | Buy | Maintains | $60 → $65 | +56.93% | Jun 13, 2025 |
Piper Sandler | Piper Sandler | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +44.86% | May 6, 2025 |
Scotiabank | Scotiabank | Buy Maintains $52 → $57 | Buy | Maintains | $52 → $57 | +37.61% | May 5, 2025 |
Financial Forecast
Revenue This Year
911.65M
from 739.02M
Increased by 23.36%
Revenue Next Year
1.11B
from 911.65M
Increased by 21.43%
EPS This Year
-3.15
from -3.56
EPS Next Year
-2.69
from -3.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 936.6M | 1.2B | 1.6B | ||
Avg | 911.7M | 1.1B | 1.4B | ||
Low | 837.9M | 980.0M | 1.1B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 26.7% | 31.4% | 48.3% | ||
Avg | 23.4% | 21.4% | 23.4% | ||
Low | 13.4% | 7.5% | 0.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.15 | -1.13 | -0.86 | ||
Avg | -3.15 | -2.69 | -2.10 | ||
Low | -3.39 | -2.99 | -2.55 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.